{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-001504","form_type":"8-K","ticker":"LQDA","cik":"0001819576","company_name":"Liquidia Corp","filed_at":"2024-01-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.682215+00:00","generated_at":"2026-06-07T03:20:08.161099+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Liquidia raises $100M: $75M equity private placement + $25M debt from HCR","bullets":["Private placement of 7,182,532 shares at $10.442/share (8% discount to Jan 3 close) to Patient Square Capital affiliate; gross proceeds ~$75M.","Fourth amendment to RIFA funds additional $25M from HCR, bringing total drawn to $67.5M; remaining $32.5M available upon mutual agreement.","CFO says combined $126M (including Dec 2023 offerings) positions company to reach profitability if YUTREPIA launches by April 2024.","Proceeds to fund commercial development, clinical trials for YUTREPIA (PAH/PH-ILD) and L606, plus general corporate purposes.","Equity issuance expected to close January 8, 2024; no broker fees paid."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-001504","json":"https://secwatch.observer/filing/0001104659-24-001504.json","markdown":"https://secwatch.observer/filing/0001104659-24-001504.md","text":"https://secwatch.observer/filing/0001104659-24-001504.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819576/000110465924001504/0001104659-24-001504-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819576/000110465924001504/tm242158d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T03:20:08.161099+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"48f942284ab92fe233dc97241ec60e83e51207ad","claim":"Liquidia Corp entered into Registration Rights Agreement with Legend Aggregator, LP valued at Agreement to file registration statement for resale of Private Placement Shares (effective 2024-01-04).","evidence_excerpt":"In connection with the Private Placement, on January 4, 2024, the Company entered into a registration rights agreement (the “Registration Rights Agreement”) with the Purchaser.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819576/000110465924001504/0001104659-24-001504-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Legend Aggregator, LP"},{"label":"Value","value":"Agreement to file registration statement for resale of Private Placement Shares"},{"label":"Effective","value":"2024-01-04"}],"fact_type":"material_agreement"},{"claim_id":"c45ce608bc3ee6ca7daea66ddde67d52c72282ef","claim":"Liquidia Corp entered into Fourth Amendment to Revenue Interest Financing Agreement with HealthCare Royalty Partners IV, L.P. valued at $25,000,000 additional funding (effective 2024-01-03).","evidence_excerpt":"On January 3, 2024, Liquidia Technologies and HCR entered into a Fourth Amendment to the Financing Agreement (the “Fourth Amendment”) to fund an additional $25.0 million thereunder.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819576/000110465924001504/0001104659-24-001504-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"HealthCare Royalty Partners IV, L.P."},{"label":"Value","value":"$25,000,000 additional funding"},{"label":"Effective","value":"2024-01-03"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}